LSE · AOTI.L
AOTI, Inc.
£1.33+£0.01 (+0.76%)
AOTI, Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.67% below the high.
Loading market information…
LSE · CREO.L · GBp
Stock price, earnings
Quote as of Oct 29, 2026, 03:06 PM UTC. Cached market data; not a live quote.
One-year closing-price history · GBp. Historical prices are not a forecast.
Creo Medical Limited’s quoted price sits in the lower half of its reported 52-week range, 38.51% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Creo Medical Limited’s next earnings report is currently expected on Jun 2, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Creo Medical Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Creo Medical Limited, a UK-based enterprise and subsidiary of Creo Medical Group plc, specializes in the innovation and creation of electrosurgical medical devices for surgical endoscopy applications. Founded in 2003 as MicroOncology Ltd and headquartered in Chepstow, the company's core offering is Croma, an advanced energy platform. This platform is engineered to power a diverse collection of multi-modal instruments, thereby enhancing therapeutic interventions for both medical professionals and patients. Its extensive product portfolio includes specialized tools such as Speedboat Inject, an adaptable energy instrument designed for flexible endoscopic procedures; Speedboat Slim, a flexible bipolar radiofrequency (RF) and microwave device for precise tissue cutting and coagulation; MicroBlate Fine, a microwave needle for ablation; MicroBlate Flex, a flexible microwave ablation device; SlypSeal Flex, a flexible haemostasis device engineered to control upper and lower gastrointestinal bleeds; and SpydrBlade Flex, a flexible scissor-like instrument that integrates bipolar RF and microwave technology to grasp, cut, and coagulate highly vascularized tissues.
Latest available per-share figures in GBP. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:57 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2022 | Sep 9, 2022 | -£0.07 | £13.64M0.0% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
£1.33+£0.01 (+0.76%)
AOTI, Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.67% below the high.
£0.90£0.00 (0.0%)
INSPECS Group plc’s quoted price sits in the upper half of its reported 52-week range, 14.29% below the high.
£1.90£0.00 (0.0%)
Kooth plc’s quoted price sits in the upper half of its reported 52-week range, 6.65% below the high.
£0.10+£0.00 (+2.63%)
Ondine Biomedical Inc.’s quoted price sits in the upper half of its reported 52-week range, 37.1% below the high.
£6.80+£0.07 (+1.04%)
Hemogenyx Pharmaceuticals Plc’s quoted price sits in the lower half of its reported 52-week range, 44.26% below the high.
£0.06+£0.00 (+8.11%)
hVIVO plc’s quoted price sits in the lower half of its reported 52-week range, 45.45% below the high.
€0.45+€0.01 (+1.37%)
Novacyt S.A.’s quoted price sits in the lower half of its reported 52-week range, 57.21% below the high.
£0.04+£0.00 (+6.12%)
ImmuPharma PLC’s quoted price sits in the lower half of its reported 52-week range, 67.09% below the high.
